Roivant Sciences Ltd at H.C. Wainwright BioConnect Investor Conference Transcript
Okay. Great. Welcome, everybody. Thanks for joining us today at the conference. I'm Doug Tsao, senior analyst at HC Wainwright. We're thrilled to have with us Roivant represented by Richard Pulik, the company's CFO.
So we'll sort of jump right into it because we only have 20 minutes.
So we're -- Richard, we're almost a year into the launch of VTAMA. Scripts got off to a really fast start. We saw a little bit of a slowdown at the end of '22 and the first couple of months of '23. Now, some of that was probably related to typical seasonality that you see in the first quarter at the start of the year.
We have seen a little bit of a step up again in the last few weeks. What do you think is the driver of that? And what are your perspectives on the near-term outlook for that product?
No. So I think, look, we have -- just to step back for folks who may not be familiar with the product. This is the first innovative topical that's been launched in the space in 25
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
